Baobab AiBIO

Baobab AiBIO is a South Korean biotechnology company specializing in structure-based drug design and development for intractable and rare diseases. Founded in 2018 as a faculty startup from Yonsei University, the company leverages a proprietary drug discovery platform, Bio-Space Voyager, which integrates artificial intelligence, quantum mechanics, and cryogenic electron microscopy (Cryo-EM) to analyze three-dimensional protein structures at atomic resolution. Baobab AiBIO's pipeline includes small molecule candidates targeting undruggable proteins in oncology and neurology, such as TEAD inhibitors for glioblastoma and TMEM175 activators for Parkinson's disease, alongside clinical-stage recombinant protein therapeutics like GF-103 for wet age-related macular degeneration.